IOL Life Sciences incorporated as a subsidiary of IOL Chemicals and Pharmaceuticals
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
All the capex is being met through internal accruals only
Under this initiative, 700 meals will be provided every day to four hospitals in Mumbai
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
JEEN’s portfolio includes a diverse range of specialized active ingredients, botanical extracts, and complexes serving functional applications for skin and hair care
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
It will be marketed under the brand name Molunamax
Subscribe To Our Newsletter & Stay Updated